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Human noroviruses (HuNoVs) are a major cause of viral gastroenteritis, with an estimated 3 million cases per year in the United
Kingdom. HuNoVs have recently been isolated from pet dogs in Europe (M. Summa, C.-H. von Bonsdorff, and L. Maunula, J
Clin Virol 53:244 –247, 2012, http://dx.doi.org/10.1016/j.jcv.2011.12.014), raising concerns about potential zoonotic infections.
With 31% of United Kingdom households owning a dog, this could prove to be an important transmission route. To examine
this risk, canine tissues were studied for their ability to bind to HuNoV in vitro. In addition, canine stool samples were analyzed
for the presence of viral nucleic acid, and canine serum samples were tested for the presence of anti-HuNoV antibodies. The re-
sults showed that seven different genotypes of HuNoV virus-like particles (VLPs) can bind to canine gastrointestinal tissue, sug-
gesting that infection is at least theoretically possible. Although HuNoV RNA was not identified in stool samples from 248 dogs,
serological evidence of previous exposure to HuNoV was obtained in 43/325 canine serum samples. Remarkably, canine sero-
prevalence for different HuNoV genotypes mirrored the seroprevalence in the human population. Though entry and replication
within cells have not been demonstrated, the canine serological data indicate that dogs produce an immune response to HuNoV,
implying productive infection. In conclusion, this study reveals zoonotic implications for HuNoV, and to elucidate the signifi-
cance of this finding, further epidemiological and molecular investigations will be essential.
Human noroviruses (HuNoV) are a major cause of viral gas-troenteritis worldwide, with an estimated 3million cases each
year in theUnitedKingdomalone (1).HuNoVaremembers of the
Caliciviridae family, which have a single-stranded positive-sense
RNA genome and can cause a variety of disease manifestations in
awide range of species. TheNorovirus genus itself is divided into at
least six different genogroups based on capsid sequences (2, 3).
HuNoV strains fall into genogroups I, II, and IV (GI, GII, and
GIV). GII strains are responsible for 96% of HuNoV cases world-
wide, withGII.4 genotypes being themost prevalent overall (4). In
humans, HuNoV typically causes acute diarrhea, vomiting, and
abdominal cramps, with the illness lasting on average 28 to 60 h
(5). Infection is most common in health care institutions such as
hospitals and long-term-care facilities (6), but outbreaks are often
reported in association with schools, restaurants, cruise ships, and
other settings such as military bases (7).
Transmission of HuNoV is via contact with feces or vomit,
which occurs predominantly through direct person-to-person
contact or contaminated food and water (8). Zoonotic transmis-
sion of HuNoV has also been proposed as a hypothetical route of
infection (9). Both cattle and pigs have come under scrutiny for
their potential role in transmitting HuNoV over the past decade.
This has been precipitated by the identification of GII.4 HuNoV
RNA in the stools of farmed pigs and cattle (10, 11). Furthermore,
over half of the pigs in a U.S. report were seropositive to both GI
and GII human noroviruses (12). This finding was supported by a
study that demonstrated that human strains can replicate and in-
duce an immune response in gnotobiotic pigs (13).
Dogs were first suggested to be potential zoonotic vectors of
HuNoV in 1983, following an outbreak of norovirus gastroenteri-
tis in an elderly-care home (14). Just prior to development of
clinical symptoms in humans, the owner’s dog was sick on multi-
ple occasions around the home. Serological testing of the dog later
revealed a moderate titer to HuNoV antigen by electron micros-
copy, whereas control dogs were all seronegative. Later evidence
linking dogs with HuNoV infections in humans followed in an
epidemiological study that showed that seropositivity to HuNoV
in humanswas higher if therewas a dog in the household (15), and
anti-HuNoV antibodies have recently been identified in dogs
across Europe (16).
In 2012 it was reported that HuNoV could be detected in stool
samples from pet dogs (17). Samples were collected from 92 dogs
if the dog or owner had recently suffered from diarrhea or vomit-
ing. Canine stool samples were tested for the presence of GI, GII,
and GIV HuNoV, and 4 dogs were found to be positive for GII
HuNoV. In one case, the HuNoV strain identified was identical to
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that isolated from stools of the owner.While the presence of iden-
tical sequences does not formally confirm active replication in
dogs, the levels of viral RNA observed would suggest that at least
limited replication had occurred.
The primary step for HuNoV infection of cells requires
HuNoV binding to complex carbohydrates known as histo-blood
group antigens (HBGAs) (18). As well as being expressed on
erythrocytes, HBGAs are expressed on the surface of epithelial
cells of the gastrointestinal, genitourinary, and respiratory tracts
and can be secreted by these cells into bodily fluids, including
saliva (19). Internalization of viral particles into cells occurs fol-
lowingHuNoV attachment toHBGAs in vitro, and therefore it has
been proposed that the primary step for HuNoV uptake into cells
isHuNoVbinding to theHBGAs. The importance ofHBGAbind-
ing in human infections has been demonstrated by experimental
challenge studies. These have shown that susceptibility to HuNoV
infection is related to expression of HBGAs in the gastrointestinal
tract (20, 21). Approximately 20% of Caucasians do not express
gastrointestinal HBGAs due to the lack of a functional fucosyl-
transferase 2 (FUT2) gene (“nonsecretors”), and consequently
these individuals have a significantly reduced susceptibility to in-
fection with noroviruses.
For dogs to be susceptible to human norovirus, it is reasoned
that dogs must express HBGAs in their gastrointestinal tracts. Al-
though canine blood types bear no resemblance to the human
system, and indeed canine erythrocytes cannot be agglutinated by
HuNoV (22), we have recently demonstrated that dogs do express
HBGAs in their saliva and on the surface of intestinal epithelial
cells (23). This indicates that dogs express the relevant attachment
factors for the primary step in HuNoV infection, which is indica-
tive of a theoretical susceptibility to HuNoV.
With approximately 10 million dogs in the United Kingdom,
divided among 31% of the households (24), the suggestion that
HuNoV may be transmissible between these species is of consid-
erable public health concern. This study aimed to investigate the
ability of HuNoV to infect dogs and the frequency with which this
might be occurring in the United Kingdom. This has been
achieved by first exploring the relationship between canineHBGA
expression and HuNoV binding to canine tissues, and second by
determining the occurrence of current and past HuNoV infec-
tions in dogs using anHuNoVRNA survey of canine stool samples
and a serological survey of canine serum.
MATERIALS AND METHODS
Ethics statement. Collection of canine saliva samples was a nonregulated
procedure, and hence ethical approval was not required. Similarly, no
ethical approval was required for collection of canine stool and serum
samples, as these were either animal waste products, surplus to diagnostic
requirements, or derived from a previously published and ethically ap-
proved study (25). Canine gastrointestinal tissue samples were donated by
a large pharmaceutical company; the six dogs had been bred for scientific
research but were deemed unsuitable for this purpose andwere humanely
euthanized. Human saliva samples were collected as part of a previous
study (26), approved by the Nantes University Hospital Review Board
(study no. BRD02/2-P), with informed written consent obtained from all
saliva donors.
Samples. Stool samples were collected from dogs admitted to six par-
ticipating United Kingdom veterinary clinics in Suffolk, Kent, Lincoln-
shire, Middlesex, and Cambridgeshire. Dogs were recruited to the study if
they passed stools while hospitalized, andwith owner consent, stools were
collected by veterinary personnel. An additional 10 sampleswere collected
from Wood Green Animal Shelter, Cambridgeshire, United Kingdom,
from dogs suspected to have infectious gastroenteritis. All stool samples
were stored at 20°C until and during transportation to the laboratory,
whereafter they were stored at80°C prior to extraction of RNA. Control
stool samples from non-veterinary patients were collected from healthy
dogs ownedby veterinary staff, aswell as fromdogs at participating board-
ing kennels. Basic case data were recorded for each dog fromwhich a stool
sample was collected, including age, breed, sex, reason for admission, and
any recent history of enteric disease.
Canine serum samples were obtained from two separate dog popula-
tions. Samples from 1999 to 2001 were collected from a rehoming kennel
as part of an existing study (25). Serum samples from 2012 to 2013 were
surplus to diagnostic requirements, obtained from veterinary patients at
the Royal VeterinaryCollege, London, fromwhich bloodwas collected for
biochemical analysis for diagnostic purposes.
Canine saliva samples were collected from 23 dogs at Wood Green
Animal Shelter, Huntingdon, United Kingdom (numbered 1 to 23), and a
further 3 samples were collected from three of the dogs at a pharmacolog-
ical research company in the United Kingdom (labeled D, E, and F). The
dogs at the animal shelter were mixed breeds, whereas the research dogs
were beagles. Sample collection was achieved using a children’s swab (Sa-
limetrics, Newmarket, United Kingdom), from which saliva was ex-
tracted. Human saliva samples were collected as part of a previous study
(26).
Canine tissue samples were donated from six healthy 18-month-old
female dogs (labeled A to F) that had been humanely euthanized as sur-
plus to industry research requirements. Sections of the gastrointestinal
tract (1 cm2) were dissected as previously described (23). Briefly, either
samples from the duodenum, jejunum, ileum, cecum, and colon were
fixed and then embedded in paraffin and sectioned, or sections were lysed
and homogenized to generate scraping samples.
RNA extraction and reverse transcription-quantitative PCR (qRT-
PCR). Stools were diluted 10% (wt/vol) in phosphate-buffered saline
(PBS) (pH 7.2), and solids were removed by centrifugation at 8,000  g
for 5 min. Viral nucleic acid was extracted from 140l of each clarified
stool suspension with the GenElute mammalian total RNA miniprep kit
(Sigma-Aldrich) according to the manufacturer’s instructions.
An internal extraction control was added to each sample during nu-
cleic acid extraction to verify removal of PCR inhibitors and enable pre-
cise quantification of viral nucleic acid. A fixed amount of equine arteritis
virus (EAV) RNAwas added with the lysis buffer to each sample to obtain
an EAV concentration of approximately 1  108 copies per ml of fecal
suspension. qRT-PCR was used to screen for genogroup I (GI) and geno-
group (GII) HuNoV using previously published primer-probe sets (27).
Samples were also screened for canine-specific noroviruses using a
primer-probe setdesigned to identify sixdifferent strainsof caninenorovirus
(CNV) (Table 1) aswell as canine parvovirus (CPV) and canine enteric coro-
navirus (CECoV) in a duplex assay as previously reported (28).
Using a 1-step qRT-PCR protocol, 2l of extracted RNAwas added to
2 Precision OneStep qRT-PCR MasterMix (PrimerDesign Ltd.), 6
pmol/l primers, and 3 pmol/l probe. The thermal cycle protocol, used
with a ViiA7 qPCR machine (AB Applied Biosystems), was as follows:
55°C for 30 min, inactivation of reverse transcriptase at 95°C for 5 min,
and then 40 cycles consisting of denaturation at 95°C for 15 s and then
annealing and elongation at 60°C for 1 min.
VLP production. Virus-like particles (VLPs) of seven different
HuNoV genotypes (GI.1, GI.2, GI.3, GII.3, GII.4, GII.6, and GII.12) and
VLPs of three strains of CNVwere produced using a previously described
method (28–30). Accession numbers for the HuNoV strains used to gen-
erate the VLPs for this study are listed in Table 2. Recombinant baculovi-
ruses containing human or canine norovirus VP1 protein were generated,
and then VLPs were produced by infection of Hi5 insect cells. VLPs were
released from the infectedHi5 cells by freeze-thawing and then clarified by
removing cellular debris (6,000 g, 30min) and baculovirus (14,000 g,
30 min). VLPs were partially purified through a 30% (wt/vol) sucrose
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cushion in TNC buffer (50mMTris HCl [pH 7.4], 150mMNaCl, 10mM
CaCl2) containing the protease inhibitor leupeptin at 150,000 g for 2 h.
The pelleted VLPs were resuspended in TNC and further purified by
isopycnic centrifugation in cesium chloride (150,000  g, 18 h). The re-
sultant VLP bands were collected by puncture, and the solution contain-
ing VLPs was dialyzed against PBS prior to quantification by the bicin-
choninic acid (BCA) protein assay (Thermo Scientific) and storage at
80°C. GI.1 and GII.4 VLPs were visualized by electron microscopy to
confirm correct particle assembly (Fig. 1), and as all VLPs in this study
were made using an identical protocol and formed a defined band on a
cesium chloride gradient, this was deemed sufficient to confirm VLP for-
mation for each genotype.
Enzyme-linked immunosorbent assay (ELISA) procedure. Ninety-
six-well polystyrene microtiter plates (Nunc Maxisorb; Fisher Scientific)
were coated overnight at 4°C with 25 ng of each GI strain (3 strains, total
of 75 ng/well) or each GII strain (4 strains, total of 100 ng/well) in 0.05 M
carbonate-bicarbonate buffer (pH 9.6). Plates were washed three times
with 0.05%Tween 20 in phosphate-buffered saline (PBS-T) before block-
ing in 5% skimmilk–PBS-T for 1 h at 37°C and then three PBS-T washes.
Plates were then incubated for 3 h at 37°C with a 1:50 dilution of each
serum sample in duplicate in 5% skim milk–PBS-T. Pooled human sera
(Sigma-Aldrich), diluted 1:400, and 100 ng pooled GII human norovirus
VLPs were used as a positive control. After three washes with PBS-T, 50l
of horseradish peroxidase (HRP)-conjugated anti-canine or anti-human
IgG antibody (both from Sigma-Aldrich) diluted 1:5,000 or 10,000, re-
spectively, in 5% milk–PBS-T was added to each well and incubated at
37°C for 1 h. The plates were washed three times with PBS-T and bound
antibody detected with 50 l tetramethylbenzidine (TMB) (Sigma-Al-
drich), followed by incubation at room temperature for 10 min. The re-
action was stopped with 1 N H2SO4, and the optical density at 450 nm
(OD450) was read (Spectromax M2 plate reader; Molecular Devices).
To eliminate the possibility that nonspecific components of the VLP
preparation were identified by the canine sera, an antigenically distinct
vesivirus 2117 VLP was included in the assay. The OD450s of serum sam-
ples incubated on either carbonate-bicarbonate buffer-coated wells or
vesivirus 2117-coatedwells were highly comparable, with the exception of
8% of dogs which displayed reactivity to vesivirus 2117, which was a
limitation of this methodology (data not shown). It was suspected that
reactivity to vesivirus 2117 could be due to cross-reactivitywith the related
canine calicivirus, but no correlation between seropositivity toHuNoV or
seropositivity to vesivirus 2117was shown (see Fig. S1 in the supplemental
material). Subsequently, the background signal for each sample was de-
termined by measuring the OD450 of serum samples incubated with car-
bonate-bicarbonate buffer alone. The background signal was then sub-
tracted from the OD450 of VLP-coated wells to generate the corrected
OD450 value. A threshold value was established as the mean of the OD450s
of all buffer-coated cells plus 3 standard deviations. A serum sample was
considered positive when the correctedOD450 was higher than the thresh-
old. Any serum samples showing a positive response to pooled HuNoV
VLPs were subjected to further testing with individual HuNoV VLPs.
Plates were coated with 25 ng of individual VLPs in carbonate-bicarbon-
ate buffer and the protocol then repeated as described above.
Evaluation of serological cross-reactivity between different norovirus
strains was achieved using VLP competition assays and antibody compe-
tition assays. For the VLP competition assays, plates were first coated with
25 ng/well of VLP overnight at 4°C. Canine serum was incubated with a
range of concentrations of either pooled GI or GII HuNoV VLPs or
pooled CNV VLPs (0.5, 1, 2, and 4 g/ml) for 1 h at 37°C. Vesivirus 2117
VLP was incubated with the canine sera as a negative control. After the
incubation period, 50 l of each serum-VLP combination was added to
the previously VLP-coated plates. The remainder of the ELISA protocol
was followed as detailed above. The concentration of VLP required to
block 50% binding (50% effective concentration [EC50]) was calculated
by fitting sigmoidal curves to the serial dilution data. Samples unable to
block 50% of binding at the highest dilution tested were assigned an EC50
of 2.5 the assay upper limit of detection.
For the antibody competition assays, polyclonal anti-norovirus VLP
antibodies were generated by immunization of a rabbit (GII.4HuNoV) or
rat (CNV) as previously described (31). Plates were coatedwith 25 ng/well
of GII.4 VLP overnight at 4°C, and then after blocking for 1 h in 5% skim
milk–PBS-T, rabbit anti-GII.4 or rat anti-CNV antibody was added to the
wells serially diluted in 5% skim milk–PBS-T for 1 h. Following three
TABLE 2 GenBank Accession numbers of HuNoV strains used to
generate VLPs
HuNoV genotype GenBank Accession no.
GI.1 NC_001959.2
GI.2 KP064095
GI.3 KP064096
GII.3 KP064097
GII.4 AF472623
GII.6 KP064098
GII.12 KP064099
FIG 1 Characterization of HuNoV VLPs. Electron micrographs of represen-
tative GI and GII HuNoV VLPs (GI.1 and GII.4) with negative staining are
shown.
TABLE 1 Primers and probe sequences used in qPCR screen of canine stool samples for noroviruses
Virus Primer and probe sequencesa Reference
Canine norovirus Forward, GCTGGATGCGGTTCTCTGAC; reverse, TCATTAGACGCCATCTTCATTCAC; probe,
FAM-AGCGAGATTGCGATCTCCCTCCCACAT-BHQ
28
Human GI norovirus Forward, CGYTGGATGCGNTTYCATGA; reverse, CTTAGACGCCATCATCATTYAC; probe,
FAM-AGATYGCGATCYCCTGTCCA-TAMRA
27
Human GII norovirus Forward, CARGARBCNATGTTYAGRTGGATGAG; reverse, TCGACGCCATCTTCATTCACA;
probe, FAM-TGGGAGGGCGATCGCAATCT-TAMRA
27
Equine arteritis virus
(internal control)
Forward, CATCTCTTGCTTTGCTCCTTAG; reverse, AGCCGCACCTTCACATTG; probe,
Cy5.5-CGCTGTCAGAACAACATTATTGCCCAC-BHQ2
51
a FAM, 6-carboxyfluorescein; TAMRA, 6-carboxytetramethylrhodamine.
Evidence for Human Norovirus Infection of Dogs
June 2015 Volume 53 Number 6 jcm.asm.org 1875Journal of Clinical Microbiology
 o
n
 June 3, 2016 by 67683460
http://jcm.asm.org/
D
ow
nloaded from
 
washes in PBS-T, GII.4-positive canine serumwas added and the remain-
der of the ELISA protocol followed as described above.
Assays to assess VLP binding to saliva and gastrointestinal scrapings
used the ELISA protocol as described above, with the addition of 100 ng
HuNoVVLPs per well in 5% skimmilk–PBS-T after the 1-h blocking step
with 5% skim milk–PBS-T. VLPs were incubated at 37°C for 1 h with the
saliva or gastrointestinal scraping samples and then detected using poly-
clonal anti-GI.1 (rabbit 130) or anti-GII.4 (rabbit 132) primary antibod-
ies. Goat HRP-conjugated anti-rabbit antibody (Interchim, France) was
used as the secondary antibody as previously described. The saliva pheno-
typing assay used the ELISA protocol as detailed above, with variations as
described in a previous study (23).
SDS-PAGE and Western blot analysis. VLPs were heated to 95°C for
5 min in the presence of SDS loading buffer and electrophoresed on
12.5% SDS-polyacrylamide gels. For Coomassie blue staining, the gels
were incubated with Coomassie blue for 1 h at room temperature prior
to destaining. Proteins were transferred from SDS-polyacrylamide gels
to polyvinylidene difluoride membranes for Western blotting. The
membranes were blocked for 1 h at room temperature with 5%milk in
PBS-T and then incubated overnight at 4°C with canine serum samples
diluted 1:1,000. The excess antibody was washed three times in PBS-T
and incubated for 1 h with anti-canine IgG secondary antibody con-
jugated to horseradish peroxidase (Sigma-Aldrich) diluted 1:10,000 in
5% milk–PBS-T. After washing away excess secondary antibody, the
bands were detected using enhanced chemiluminescence reagent (GE
Healthcare).
Tissue samples and immunohistochemical analysis. Tissue sections
from the gastrointestinal tracts of six dogs were deparaffinized through
baths of LMR-SOL (1-bromopropane, 2-methylpropane-2-ol, and aceto-
nitrile), followed by rehydration with successive baths of 100, 90, 70, and
50% ethanol. Endogenous peroxidase activity was blocked with 0.3% hy-
drogen peroxide in PBS.Nonspecific bindingwas blockedwith 3%bovine
serum albumin (BSA) in PBS. H and A antigen detection was then per-
formed as previously reported (23). To assess the ability of VLPs to bind to
tissue sections, after blocking, 1 g/ml VLPs was incubated with the sec-
tions overnight at room temperature. Anti-HuNoVprimary antibodywas
then incubated with the tissue sections for 1 h at 37°C. After three washes
in PBS, sections were incubated with secondary anti-rabbit biotinylated
antibody (Vector Laboratories, Burlingame, CA) diluted in 1% BSA in
PBS for 1 h. Sections were washed three times in PBS prior to addition of
HRP-conjugated avidin D (Vector Laboratories, Burlingame, CA) also
diluted in 1% BSA in PBS. Substrate was added to the slides (AEC kit;
Vector Laboratories, Burlingame, CA), followed by Mayer’s hematoxylin
solution (Merck, Whitehouse Station, NJ) for contrast staining.
RESULTS
HuNoV VLPs bind to canine gastrointestinal samples in ELISA-
based assays. Saliva samples from 26 dogs (1 to 23 and D to F),
and duodenal scrapings from 6 dogs (A to F) were analyzed in
ELISA-based assays for their ability to bind to HuNoV VLPs (Fig.
2). All canine samples were phenotyped for HBGA expression in a
previous study (23). It was therefore known thatH antigen expres-
sion was present in every canine sample, and A antigen and Lewis
antigen expression was polymorphic. Human saliva samples rep-
resenting the major HBGA phenotypes present in humans were
used as controls. These human samples included saliva from a
nonsecretor individual (no HBGA expression) and saliva from
humans expressing either A antigen, B antigen, orH antigen alone
(O phenotype). Saliva samples with variation in Lewis antigen
expression (/) were also included.
In the saliva binding assay (Fig. 2A), the nonsecretor human
sample was unable to bind to HuNoV VLPs, as expected based
on previous reports (18). In contrast, all canine saliva samples
and all secretor human samples were able to bind to HuNoV
GI.1 and GII.4 VLPs. There were comparable OD450 values for
the canine and human saliva samples, indicative of similar lev-
els of binding.
VLPs of seven different HuNoV genotypes were used to assess
their ability to bindduodenal scrapings from six dogs (A to F) (Fig.
2B). Human saliva samples from an A antigen-positive, Lewis an-
tigen-positive (A) individual and an A antigen-negative, Lewis
antigen-negative (O) individual were used as positive controls;
both samples were shown (Fig. 2A) to bind to GI.1 and GII.4
HuNoV VLPs. Figure 2B demonstrates that canine duodenal
scrapings could bind to every HuNoV genotype tested. Individual
variation between the samples was identified; for example, canine
samples D, E, and F showed decreased binding to GI.2 and GII.4
HuNoV VLPs. Other dogs however, most notably dogs B and C,
were able to bind to all HuNoV VLPs tested. This was not appar-
ently related to HBGA phenotype; all dogs were H antigen posi-
tive, and dogs C and E were A antigen positive, whereas dogs A, B,
D, and F were A antigen negative (as previously reported [23]). In
addition, dogs were phenotyped for Lewis antigen, with dogs A
andB being Lewis positive and the remainder Lewis negative (data
not shown). Variation in OD450 scales between genotypes was
arbitrary due to the primary antibody used; for detection of the GI
VLPs, the primary antibody used had been raised against GI.1,
whereas for the GII VLPs, the primary antibody was raised against
GII.4.
HuNoV VLPs bind to canine gastrointestinal tissue sections.
To determine whether HuNoV VLPs are able to bind to canine
gastrointestinal tissues, fixed sections of duodenum from two
dogs (B and C) were incubated with HuNoV VLPs for 1 h, and
then immunohistochemistry (IHC) was used to detect binding of
HuNoV VLPs to the tissue surface. As polymorphism for the A
antigen is present in dogs (approximately 50% are A antigen pos-
itive [23]) and due to the known interaction between A antigen
and HuNoV (32), HBGA phenotyping was also required. Confir-
mation of the presence or absence of H antigen and A antigen in
the tissue sections used for the VLP binding was achieved by in-
cubating the tissue sections with Ulex and anti-A antigen anti-
body, respectively, and IHC was performed. This demonstrated
that dog C was A antigen positive and dog B was A antigen nega-
tive, hence enabling comparison of HuNoV VLP binding to ca-
nine samples representing the two major HBGA phenotypes. H
antigen expressionwas not detectable in theA-positive dog, which
is understood to be due to the ability of the A antigen to mask the
H antigen, therefore preventing detection by Ulex lectin binding
(33).
Figure 3 demonstrates that GI.1 and GII.4 HuNoV VLPs can
bind to both A antigen-positive and A antigen-negative dogs. In
addition it was shown that HuNoV VLP binding has a pattern of
expression similar to that of H and A antigen. Given the known
interaction between HBGAs and HuNoVs, these similar binding
patterns were expected (18).
HuNoV RNA was not detected in canine stool samples. A
total of 248 canine stool samples were collected and analyzed for
the presence ofHuNoVRNA. Stool samples and clinical data were
collected from131 dogs admitted to veterinary clinics and a rescue
kennel distributed across the United Kingdom between August
2012 andMay 2014. Themean age of the dogs was 5.1 years (stan-
dard deviation, 4.3 years), with 56 different breeds represented. A
total of 50.1% of these samples were from dogs with clinical signs
of primary gastroenteritis. Control samples were collected from
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117 healthy dogs (mean age, 5.6 years; standard deviation, 3.6
years) from boarding kennels or belonging to veterinary staff.
Nucleic acid extraction and qPCRwere successfully performed
on 248 stool samples as determined by constant threshold cycle
(CT) values from the internal extraction control RNA. Samples
were tested by qPCR for the presence of HuNoV and CNV. No
samples were identified as being positive for any noroviruses, in-
dicating that the overall prevalence of noroviruses in this popula-
tion at the time of sample collectionwas1.5% (Wilson binomial
approximation; confidence interval, 95%). To confirm the effi-
cacy of the screening method, samples were also tested for the
presence of two additional canine viruses previously reported to
FIG 2 HuNoV binding to canine samples in ELISA-based assays. Saliva from 20 six dogs (A) and duodenal scrapings from six dogs (B) were analyzed to assess
their ability to bind to HuNoV VLPs. GI.1 and GII.4 HuNoV VLPs were used to assess binding to both saliva and duodenal samples, and an additional five
genotypes of HuNoV VLPs were used in the duodenal sample binding assays. Human saliva samples representing a range of HBGA phenotypes were used as
positive and negative controls, i.e., secretor negative (se) or O/A/B antigen positive, with Lewis expression represented by/. All experiments were performed
in duplicate, with error bars representing the standard error for each sample.
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be present in the United Kingdom, canine parvovirus (CPV) and
canine enteric coronavirus (CECoV). Enteric viruses, either CPV
or CECoV, were detected at high titer (107 copies/ml stool) in
17.9% (12/67) of dogs admitted with primary gastroenteritis. No
viruses were detected at titers above the positive threshold of the
assay in dogs without gastroenteritis.
HuNoV-specific antibodies are present in dogs. Seven geno-
types of HuNoV VLPs were used in ELISAs to screen for anti-
HuNoV antibodies in a total of 325 dogs. Serum samples were
collected from two groups of dogs, i.e., 223 samples collected in
1999 to 2001 (cohort A) and 102 samples collected in 2012 to 2013
(cohort B). Three GI HuNoV VLPs (GI.1, GI.2, and GI.3) were
pooled for preliminary assays, as were four GII VLPs (GII.3, GII.4,
GII.6, and GII.12).
The primary anti-HuNoV antibody screen identified anti-
HuNoV antibodies at detectable levels in sera from 43 dogs, 24
from cohort A (10.7%) and 19 from cohort B (18.6%) (Table 3).
Of these 43 dogs, 32.5% were seropositive for both GI and GII
HuNoV, whereas the remainder were seropositive for either GI or
GII HuNoV. Seropositivity to CNV in the same canine serum
FIG 3 Binding of HuNoVVLPs to canine gastrointestinal tissue sections. HuNoVVLPs (GI.1 andGII.4) were incubated with tissue sections prior to staining for
immunohistochemical analysis. A positive signal, either VLP binding or HBGA expression, is represented by red-brown staining. Two different canine pheno-
types, i.e., a dog expressing A antigen (A positive), and a dog negative for A antigen expression, were compared, as presented previously (23).
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samples has previously been reported (28), and these data have
been added to Table 3 for comparison. The age of the dog at time
of sampling was known for 93/102 dogs in cohort B. No relation-
ship between seropositivity to HuNoV and age was identified
(data not shown).
To estimate the magnitude of the canine anti-HuNoV anti-
body response, anti-HuNoV titers were determined for 21/23
samples seropositive to GI HuNoV and 33/35 samples seroposi-
tive to GII HuNoV. As presented in Table 4, the antibody titers to
GI in the 21 dogs seropositive in the primary ELISA screen are
relatively low, but the OD450 values obtained in the titer ELISA
showed strong consistency in comparison with the original ELISA
screen. For the majority of the anti-GII HuNoV-positive serum
samples, a similarly low antibody titer (mode, 1:100) was deter-
mined, but in contrast to the case for GI, three samples (9% of
GII-seropositive samples tested) had antibody titers of 1:800 or
higher.
To extend the findings of the preliminary ELISAs, all canine
serum samples positive for HuNoV were entered into a second
round of ELISAs with individual genotypes of HuNoV. This was
to investigate whether it was possible to identify the HuNoV ge-
notype thatmay be eliciting the anti-HuNoV immune response. It
is acknowledged that immunological cross-reactivity does exist
between norovirus genotypes (34), and thus conclusive identifi-
cation of the primary genotype inducing antibody productionwas
not the aim of these experiments. However, the genotype to which
the highest OD450 value was induced in ELISAs was tentatively
suggested to be the major HuNoV genotype involved. For exam-
ple, a serum sample for which the OD450 was highest against GII.4
HuNoV VLPs was designated GII.4 specific for the purposes of
this study. Figure 4 presents the genotype distribution of HuNoV
GII-positive samples, comparing cohort A (1999 to 2001) with
cohort B (2012 to 2013). Our data showed that GII.4-specific an-
tibodies were most common in both cohorts, although whereas
42.1% of samples showed the highest OD450 for GII.4 in cohort A,
this figure increased to 87.5% in cohort B.
To confirm that the anti-HuNoV antibodies identified in dogs
were not merely the result of cross-reactivity to canine-specific
noroviruses, a series of blocking assayswere performed (Fig. 5). As
highlighted in Table 2, we have previously shown that seropreva-
lence to CNVwas high in the same population of dogs analyzed in
this study (28), so first it was necessary to establish that the CNV-
specific antibodies were not cross-reactive with HuNoV. This was
achieved by preincubating various concentrations of HuNoV and
CNV VLPs with a representative anti-CNV antibody-positive ca-
nine serum (serum S) and then analyzing the ability of the serum
to detect CNVVLPs (Fig. 5A). Preincubation with CNVVLPs was
clearly able to block recognition of CNV VLPs by canine serum,
whereas preincubation with GI or GII VLPs had no effect on CNV
VLP recognition. This confirmed that the epitopes recognized by
the anti-CNV antibodies were distinct from epitopes present on
HuNoV VLPs.
Next, the specificity of the anti-GII antibodies identified in
canine sera was examined using a similar VLP competition assay
with GII VLPs applied to a microtiter plate instead of CNV VLPs
(Fig. 5B). The concentration of HuNoV or CNVVLPs required to
block 50% binding to GII VLPs was calculated by fitting a sigmoi-
dal curve to the OD450 values for the serial dilution of VLPs. Seven
different canine serum samples (i to vii) identified as being posi-
tive for anti-GII antibodies were analyzed, and serum S (negative
for GII binding) was added as a negative control. For samples i to
vii, the type of VLP inducing the lowest EC50 for blocking GII VLP
recognition by canine serum was GII HuNoV VLPs. CNV VLPs
did induce a decrease in GII recognition below the upper thresh-
old of detection in 4/7 cases, but a greater concentration of CNV
VLPs than of GII VLPs was required. This suggests that a degree of
cross-reactivity between GII HuNoV and CNV is likely but that
differentiation is possible.
The final blocking assay conducted to investigate the specificity
of antibodies detected in canine serum used antibodies generated
in animals immunized solely with either CNV or GII HuNoV
VLPs (Fig. 5C). These animals, rat and rabbit, respectively, would
TABLE 3 Seroprevalence of canine and human noroviruses in two
canine cohortsa
Yr of
serum
collection
No. of
canine
samples
screened
No. (%) of sera:
HuNoV positive
CNV
positive
GI
only
GII
only
GI and
GII Total
1999–2001 223 5 (2.2) 11 (4.9) 8 (3.6) 24 (10.7) 85 (38.1)
2012–2013 102 3 (2.9) 9 (8.8) 7 (6.9) 19 (18.6) 62 (60.8)
All 325 8 (2.5) 20 (6.2) 15 (4.6) 43 (13.2) 147 (45.2)
a Serum samples were screened in ELISAs against pooled VLPs. The HuNoV GI pool
consisted of genotypes GI.1, GI.2, and GI.3. The HuNoV GII pool consisted of GII.3,
GII.4, GII.6, and GII.12. The CNV pool consisted of strains 170, C33, and HK.
TABLE 4 Anti-HuNoV antibody titers in canine serum
Anti-HuNoV
antibody titer
No. (%) of samples:
GI positive GII positive
1:50 8 (38.1) 5 (15.2)
1:100 8 (38.1) 12 (36.4)
1:200 5 (23.8) 7 (21.2)
1:400 0 6 (18.2)
1:800 0 2 (6.1)
1:1,600 0 1 (3)
FIG 4 Genotype specificity of GII HuNoV-seropositive canine samples. Se-
rum samples positive to pooledGIIHuNoVwere screened againstGII.3, GII.4,
GII.6, and GII.12 HuNoVVLPs individually. The genotype to which the high-
est OD450 reading was obtained was designated the primary genotype to which
the antibody response was elicited. The proportions of GII HuNoV-positive
samples from 1999 to 2001 (cohort A) and 2012 to 2013 (cohort B) reactive to
each GII genotype tested were compared.
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not have been exposed to natural infection, and hence antibodies
in their serum were deemed specific for their VLP immunogen.
Anti-CNV or anti-GII HuNoV serum was serially diluted and in-
cubated directly with GII VLPs applied to microtiter plates, and
then after plate washing, GII-positive canine serum (serum vi)
incubation followed. The results showed that rat CNV-specific
antiserum was unable to block recognition of GII HuNoV by ca-
nine serum, whereas rabbit GII-specific antiserum induced block-
ing of GII VLP recognition by canine serum.
Western blotting was used as alternative method to demon-
strate the presence of anti-HuNoV antibodies in canine sera. Five
serum samples identified as being positive for anti-HuNoV anti-
bodies by ELISA were selected for use in Western blots (Fig. 6). A
single serum sample (sample S2) shown to be negative for both
human and canine noroviruses was selected as a negative control.
Western blotting confirmed that canine sera from five represen-
tative samples could detect GII.4 VLPs and that this expression
was independent of recognition of genogroup IV or VI CNV.
DISCUSSION
This study sought to investigate the likelihood that dogs can be
infected with HuNoV, following initial reports that HuNoV can
be detected in the stools of dogs (17). The results of our serological
survey and VLP binding studies strongly suggest that dogs are
susceptible to HuNoV. However, the frequency with which this
occurs is deemed low based on the epidemiological results from
this report. Furthermore, the clinical implications for both dogs
and people in contact with dogs still remain to be confirmed.
FIG 5 Evaluation of cross-reactivity between antibodies against human and
canine noroviruses in canine sera. (A and B) VLP competition assays assessing
the ability of canine sera to detect CNV (A) or GII.4 HuNoV (B) in the pres-
ence of alternative norovirus VLPs were conducted. (A) A representative
CNV-positive canine serum was preincubated with serial dilutions of either
pooled GI or GII HuNoV VLPs or pooled CNV VLPs, following the method-
ology previously presented (28). (B) Seven different GII.4 HuNoV-positive
canine serum samples were preincubated with serial dilutions of either pooled
GI or GII HuNoV VLPs or pooled CNV VLPs. The concentration of VLP
required to block 50% binding (EC50) was calculated by fitting sigmoidal
curves to the serial dilution data to allow comparison between serum samples.
The dashed line represents the upper limit of detection. (C) An antibody com-
petition assay was performed using antibodies specifically raised against CNV
(rat) and GII.4 HuNoV (rabbit). Anti-CNV and anti-GII.4 antibodies were
preincubated with GII.4 VLPs on a microtiter plate, and then after three plate
washes, GII.4-positive canine serum was added and the OD450 of this interac-
tion determined.
FIG 6 Western blotting of purified VLPs using seropositive serum. Norovirus
VLPs from 4 genogroups, GI and GII (HuNoV) and GIV and GVI (CNV),
were separated by SDS-PAGE. The polyacrylamide gel was then used forWest-
ern blotting with five different canine serum samples positive to GII.4 by
ELISA and a single canine serum sample negative to all norovirus VLPs tested.
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In humans, it has been shown thatHuNoVs bind to cell surface
carbohydrates of the HBGA family prior to internalization.
HBGAs are expressed on epithelial cells of many species, and we
have recently confirmed that this includes dogs (23). This finding
led us to hypothesize that HuNoV would be able to bind to the
gastrointestinal tracts of dogs, and the ELISA and IHC data pre-
sented in this report were able to confirm this. This demonstrates
that the initial step required for HuNoV entry into canine cells is
present. However, it should be noted that rabbit hemorrhagic dis-
ease virus (RDHV), a related but distinct member of the Calici-
viridae family, can bind to HBGAs (H type 2, A antigen and B
antigen) (35), and yet there is no evidence RHDV can infect any
species other than wild and domestic rabbits of the Oryctolagus
cuniculus species. HBGA binding may be an initial step in calici-
virus-host interaction, but a subsequent host-restrictive step(s)
must be necessary for RHDV infection and potentially forHuNoV
infection in dogs.
The viral RNA survey conducted as part of this project did not
reveal any canine stool samples containing HuNoV RNA. This
implies that the incidence of HuNoV shedding by this population
of dogs is negligible, despite samples being collected from healthy
dogs (117 animals), dogs with nongastroenteric disease (64 ani-
mals), and dogs with severe gastroenteritis requiring veterinary
attention (67 animals). Inclusion of samples from the latter two
groups was essential, as it has been suggested that HuNoVmay be
more likely to infect dogs with underlying disease or immunode-
ficiency (17), and as canine-specific noroviruses are associated
with gastroenteritis in dogs (3, 36), it was hypothesized that
HuNoV infection of dogsmay cause signs of gastroenteric disease.
Gastroenteritis is a common condition in dogs, with an owner
questionnaire reporting diarrhea in 14.9% of dogs within the pre-
vious 2-week period (37) and 6% of canine veterinary consulta-
tions addressing gastroenteritis as a primary complaint (38). Of
the 67 dogs with gastroenteritis in our survey, CPV (10 dogs) and
CECoV (2 dogs) were detected in 17.9%. This proves that while
viral gastroenteritis is relatively common in dogs, noroviruses are
not a major cause of viral disease in the population of dogs sam-
pled. The likelihood of HuNoV infection in a dog resulting in
clinical signs of gastroenteritis is clearly much lower than that of
CPV and CECoV infection, and as such, there is no immediate
cause for concern by owners and veterinarians.
The absence of HuNoV-positive stool samples from dogs in
this study is in contrast to the results of Summa et al. (17), who
identified HuNoV RNA in 4/92 canine stool samples. However,
their sampling strategy was significantly different from our ap-
proach; canine stool samples were collected only if the owner had
shown symptoms of gastroenteritis within the past week, whereas
stool samples in this study were collected with no reference to
recent owner illness. HuNoV in humans is typically an acute in-
fection, with peak viral shedding occurring 2 to 4 days after infec-
tion. By 3weeks after infection, only 25% cases are still positive for
viral RNA (39). In addition, although HuNoV is responsible for
millions of infections worldwide each year, the virus is only iden-
tified in approximately 18% of human diarrheic samples submit-
ted (40). Detection of HuNoV RNA in feces can be limited by
factors such as low virus concentrations, improper storage of sam-
ples, inefficient viral RNA extraction, and the presence of fecal
reverse transcriptase inhibitors (41). Overall, this indicates that
positive identification ofHuNoV shedding in dogswill be possible
only within a very narrow time frame and that a proportion of
cases will be false negatives. This suggests that in order to confirm
that HuNoV can be shed in canine stools and to determine an
accurate prevalence rate, a much larger sample size and/or a more
focused sampling approach, e.g., collection of stool samples from
owners with confirmed HuNoV infection, will be required.
Serological analysis of 325 canine serum samples in this study
strongly suggests that dogs mount immune responses against
HuNoV.We have demonstrated that almost 20%of dogs sampled
in 2012 to 2013 had antibodies that could recognizeHuNoVVLPs.
This suggests that 1 in 5 dogs has been exposed to HuNoV in the
United Kingdom. This proportion was lower than the proportion
of dogs (43%) reported to be seropositive to HuNoV by a recent
survey across Europe (16), which may be a reflection of popula-
tion differences. An important conclusion from both studies is
that the HuNoV seroprevalence rate identified in dogs is substan-
tially lower than HuNoV seropositivity among human popula-
tions. In the United Kingdom nearly 100% of people are seropos-
itive for GII.4 (42). This indicates that either dogs are exposed
much more rarely to HuNoV or they are much less susceptible to
infection than humans. Given that in one questionnaire-based
study, 96% of dogs slept in their owners’ houses and that when
owners are at home almost 60% dogs were allowed anywhere in
the house (43), it seemsunlikely that dogswould not be exposed to
HuNoV in a household with infected humans. Therefore, we pro-
pose that dogs are susceptible toHuNoV but at amuch lower level
than humans.
It could be argued that the anti-HuNoV antibodies identified
in canine sera may have been generated in response to infection
with related nonhuman noroviruses and aremerely cross-reactive
with HuNoV. For example, anti-CNV antibodies were detected in
45.2%of serum samples used in this study (28). To investigate this
further, a series of blocking assays were performed using canine
serum samples and serum samples from rats inoculatedwithCNV
VLPs. These were able to show that the anti-GII HuNoV antibod-
ies were specific for GII HuNoV VLPs and not three different
strains of CNV (GIV and GVI). It is acknowledged that there are
other nonhuman and noncanine noroviruses to which dogs may
have been exposed, for example, swine, bovine, and feline noro-
viruses, cross-reactivity to which was not assessed. However,
cross-reactivity between genogroups is known to be limited (34),
and thus antibodies specific for feline noroviruses (GIV.2 geno-
type, the same as certain canine noroviruses) (44) or bovine no-
roviruses (GIII) are highly unlikely to cross-react with GII human
noroviruses. Swine noroviruses, however, are classified into GII
alongside human strains (45), and thus there is a greater risk of
cross-reactivity. Nevertheless, due to United Kingdom farming
practices, the frequency with which dogs in the study population
would come into contact with pigs was deemed to be significantly
lower than the frequency of contact with humans. In addition,
although the feeding of raw pork to dogs does infrequently occur,
animal noroviruses are extremely unlikely to be found in com-
mercial pet food due to United Kingdom manufacturing pro-
cesses and regulations (46).
The initial serosurvey demonstrated that dogs weremore likely
to be seropositive to GII HuNoV strains than to GI strains. This
was in line with the findings from a recent European study (16).
To explore this further, any HuNoV-positive samples were en-
tered into a second round of ELISAs with VLPs from seven indi-
vidual genotypes. This showed that the highest seroprevalencewas
to GII.4 strains. This is remarkable, as this is the most common
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genotype infecting humans worldwide. This also correlates with
the report which identifiedHuNoV in the stools of four dogs (17).
GII.4 HuNoV was detected by qPCR in the stools of 3 dogs and
GII.12 in the stools of 1 dog.
Comparison of canine serum samples from two time periods
(1999 to 2001 and 2012 to 2013) allowed analysis of the change in
the prevalence of anti-HuNoV antibodies over time. Although the
two study populations are not directly comparable (the earlier
groupwas from a rehoming kennel and the later from a veterinary
referral hospital) and the range of HuNoV strains studied was
limited, it was shown that the proportion of dogs seropositive for
HuNoV increased over this period. The prevalence of HuNoV in
humans in United Kingdom has increased over a similar time
period, from 6% in 1999 to approximately 16% in 2009 (47). It is
possible to speculate that the rise in HuNoV seroprevalence in
dogs from 1999 onwards is a reflection of the increased levels of
infection in the human population.
Overall, this study supports the hypothesis that dogs can be-
come infected with HuNoV. However, there are many questions
still outstanding. First, it is unknown whether HuNoV infection
has the potential to cause clinical disease in dogs. To answer this
definitively, experimental studies will be required. Second, assum-
ing that dogs can become infected with HuNoV, it is unknown
whether dogs will shed virus in their stools in sufficient quantities
to infect humans. It has been estimated that as few as 18 HuNoV
particles may be sufficient to cause infection in humans (48), so it
is likely that very low levels of shedding will be infectious. How-
ever, differences in the physiology of the canine and human gas-
trointestinal tracts (e.g., pH [49]) mean that it is possible that
particle infectivity varies between the species. A third unanswered
question is whether dogs play a significant role in the epidemiol-
ogy of certain HuNoV outbreaks. The majority of HuNoV out-
breaks do not occur in places where dogs are commonly found,
e.g., outbreaks on cruise ships or in hospitals, but a role for dogs
perpetuating outbreaks in communities cannot be ruled out. A
final question is whether there is potential for dogs to be coin-
fected with CNV and HuNoV simultaneously. There is also con-
cern thanCNVmay be zoonotic based on serological and receptor
studies (23, 50); hence, CNV/HuNoV coinfections may also be
possible in humans. If coinfections can occur, there would be a
theoretical risk for recombination between virus strains, leading
to generation of a novel norovirus. This may have altered viru-
lence in canine and human hosts, and ongoing surveillance for
such recombinants is deemed important.
In summary, whereas HuNoV infection of dogs has been
shown to be theoretically possible, the risk of this causing signifi-
cant clinical disease in dogs is believed to be very low. As for the
potential for HuNoV infection being transmitted between dogs
and their owners, this has yet to be established, though it is rec-
ommended that sensible hygiene precautions be taken around
pets, especially when gastroenteritis in either humans or dogs is
present in a household.
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